|
|
Some
patients develop resistance to the NNRTI's currently
routinely prescribed for those persons infected with
HIV-1. Development of a new potent antiretroviral
compound is needed for patients who have multi-drug
resistant HIV-1.
|
|
Objective
|
Capravirine
002: To determine whether the addition of capravirine
to a 3-drug regimen of will inhibit HIV replication.
Capravirine
006: To determine the optimal safe and effective dose
of capravirine in combination with a 3-drug regimen.
|
|
|
Capravirine
002: This study will evaluate two doses of capravirine
(200, 400 and 700 mg twice daily) and placebo when
taken in combination with Kaletra™ and NRTIs.
Capravirine
006: This study will evaluate three doses of capravirine
(700 and 1400 mg twice daily) and placebo when taken
in combination with Viracept™ and NRTIs.
|
Inclusion
Criteria
(partial
list)
|
- Qualifying
plasma HIV RNA greater than or equal to 1000 copies/ml
- T-cell
count greater than 50 copies/ml
- At
least 18 years old
- Volunteers
that have failed antiretroviral regimens that included
at least one but no more than three PIs, at least
one NNRTI and at least two NRTIs.
|
|
Status
__
|
Enrolling
--
|
For
more information about participating in this study
in the Los Angeles area, please call 310/358.2429
or e-mail Corie Castro at
ccastro@aidsresearch.org
|
|
We
encourage participation by women and people of color.
This
ad was reviewed and approved by the AIDS ReSearch Alliance
Institutional Review Board in March, 2003.
|
